Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis
BackgroundLevetiracetam (LEV) and oxcarbazepine (OXC) are new antiseizure medications (ASMs). In recent years, OXC monotherapy is widely used in children with epilepsy; however, no consensus exists on applying LEV monotherapy among children with epilepsy.ObjectiveThe present work focused on comparin...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2024.1336744/full |
| _version_ | 1797197773146161152 |
|---|---|
| author | Yuanyuan Liu Yanxu Wang Xingzhou Li Xiaomin Wu |
| author_facet | Yuanyuan Liu Yanxu Wang Xingzhou Li Xiaomin Wu |
| author_sort | Yuanyuan Liu |
| collection | DOAJ |
| description | BackgroundLevetiracetam (LEV) and oxcarbazepine (OXC) are new antiseizure medications (ASMs). In recent years, OXC monotherapy is widely used in children with epilepsy; however, no consensus exists on applying LEV monotherapy among children with epilepsy.ObjectiveThe present work focused on comparing the efficacy and safety of LEV and OXC monotherapy in treating children with epilepsy.MethodsWe conducted a comprehensive search across multiple databases including PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang Database, VIP, and China Biology Medicine disc, covering studies from inception to August 26, 2023. We included randomized controlled trials (RCTs) and cohort studies evaluating the efficacy and safety of LEV and OXC monotherapy for treating epilepsy in children. We utilized Cochrane Risk of Bias Tool in RevMan 5.3 software for assessing included RCTs quality. In addition, included cohort studies quality was determined using Newcastle-Ottawa Scale (NOS). A random-effects model was utilized to summarize the results.ResultsThis meta-analysis included altogether 14 studies, including 893 children with epilepsy. LEV and OXC monotherapy was not statistical different among children with epilepsy in seizure-free rate (relative risk [RR] = 1.010, 95% confidence interval [CI] [0.822, 1.242], P > 0.05) and seizure frequency decrease of ≥50% compared with baseline [RR = 0.938, 95% CI (0.676, 1.301), P > 0.05]. Differences in total adverse reaction rate [RR = 1.113, 95% CI (0.710, 1.744), P > 0.05] and failure rate because of serious adverse reaction [RR = 1.001, 95% CI (0.349, 2.871), P > 0.05] were not statistical different between LEV and OXC treatments among children with epilepsy. However, the effects of OXC monotherapy on thyroid among children with epilepsy was statistically correlated than that of LEV (thyroid stimulating hormone: standardized mean difference [SMD] = −0.144, 95% CI [−0.613, 0.325], P > 0.05; free thyroxine: SMD = 1.663, 95% CI [0.179, 3.147], P < 0.05).ConclusionThe efficacy of LEV and OXC monotherapy in treating children with epilepsy is similar. However, OXC having a more significant effect on the thyroid than that of LEV. Therefore, LEV may be safer for children with epilepsy who are predisposed to thyroid disease than OXC.Systematic Review Registrationhttps://www.crd.york.ac.uk/, PROSPERO (CRD42024514016) |
| first_indexed | 2024-04-24T06:49:17Z |
| format | Article |
| id | doaj.art-d9c54d31e5a440b9b284a48ca3e07f00 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-24T06:49:17Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-d9c54d31e5a440b9b284a48ca3e07f002024-04-22T13:18:34ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602024-04-011210.3389/fped.2024.13367441336744Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysisYuanyuan Liu0Yanxu Wang1Xingzhou Li2Xiaomin Wu3School of Public Health, Jiamusi University, Jiamusi, ChinaDepartment of Food Hygiene Monitoring, Jiamusi City Center for Disease Control and Prevention, Jiamusi, ChinaSchool of Public Health, Jiamusi University, Jiamusi, ChinaDirector, Jiamusi City Center for Disease Control and Prevention, Jiamusi, ChinaBackgroundLevetiracetam (LEV) and oxcarbazepine (OXC) are new antiseizure medications (ASMs). In recent years, OXC monotherapy is widely used in children with epilepsy; however, no consensus exists on applying LEV monotherapy among children with epilepsy.ObjectiveThe present work focused on comparing the efficacy and safety of LEV and OXC monotherapy in treating children with epilepsy.MethodsWe conducted a comprehensive search across multiple databases including PubMed, Cochrane Library, Embase, Web of Science, CNKI, Wanfang Database, VIP, and China Biology Medicine disc, covering studies from inception to August 26, 2023. We included randomized controlled trials (RCTs) and cohort studies evaluating the efficacy and safety of LEV and OXC monotherapy for treating epilepsy in children. We utilized Cochrane Risk of Bias Tool in RevMan 5.3 software for assessing included RCTs quality. In addition, included cohort studies quality was determined using Newcastle-Ottawa Scale (NOS). A random-effects model was utilized to summarize the results.ResultsThis meta-analysis included altogether 14 studies, including 893 children with epilepsy. LEV and OXC monotherapy was not statistical different among children with epilepsy in seizure-free rate (relative risk [RR] = 1.010, 95% confidence interval [CI] [0.822, 1.242], P > 0.05) and seizure frequency decrease of ≥50% compared with baseline [RR = 0.938, 95% CI (0.676, 1.301), P > 0.05]. Differences in total adverse reaction rate [RR = 1.113, 95% CI (0.710, 1.744), P > 0.05] and failure rate because of serious adverse reaction [RR = 1.001, 95% CI (0.349, 2.871), P > 0.05] were not statistical different between LEV and OXC treatments among children with epilepsy. However, the effects of OXC monotherapy on thyroid among children with epilepsy was statistically correlated than that of LEV (thyroid stimulating hormone: standardized mean difference [SMD] = −0.144, 95% CI [−0.613, 0.325], P > 0.05; free thyroxine: SMD = 1.663, 95% CI [0.179, 3.147], P < 0.05).ConclusionThe efficacy of LEV and OXC monotherapy in treating children with epilepsy is similar. However, OXC having a more significant effect on the thyroid than that of LEV. Therefore, LEV may be safer for children with epilepsy who are predisposed to thyroid disease than OXC.Systematic Review Registrationhttps://www.crd.york.ac.uk/, PROSPERO (CRD42024514016)https://www.frontiersin.org/articles/10.3389/fped.2024.1336744/fulllevetiracetamoxcarbazepinemonotherapychildren with epilepsymeta-analysis |
| spellingShingle | Yuanyuan Liu Yanxu Wang Xingzhou Li Xiaomin Wu Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis Frontiers in Pediatrics levetiracetam oxcarbazepine monotherapy children with epilepsy meta-analysis |
| title | Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis |
| title_full | Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis |
| title_short | Efficacy and safety of levetiracetam vs. oxcarbazepine in the treatment of children with epilepsy: a systematic review and meta-analysis |
| title_sort | efficacy and safety of levetiracetam vs oxcarbazepine in the treatment of children with epilepsy a systematic review and meta analysis |
| topic | levetiracetam oxcarbazepine monotherapy children with epilepsy meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fped.2024.1336744/full |
| work_keys_str_mv | AT yuanyuanliu efficacyandsafetyoflevetiracetamvsoxcarbazepineinthetreatmentofchildrenwithepilepsyasystematicreviewandmetaanalysis AT yanxuwang efficacyandsafetyoflevetiracetamvsoxcarbazepineinthetreatmentofchildrenwithepilepsyasystematicreviewandmetaanalysis AT xingzhouli efficacyandsafetyoflevetiracetamvsoxcarbazepineinthetreatmentofchildrenwithepilepsyasystematicreviewandmetaanalysis AT xiaominwu efficacyandsafetyoflevetiracetamvsoxcarbazepineinthetreatmentofchildrenwithepilepsyasystematicreviewandmetaanalysis |